A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
暂无分享,去创建一个
Keith A. Johnson | C. Jack | D. Bennett | R. Petersen | W. Jagust | K. Blennow | M. Carrillo | P. Scheltens | R. Sperling | B. Dubois | G. Frisoni | D. Knopman | H. Feldman | H. Hampel | D. Knopman | D. Bennett
[1] D. Perani. Faculty Opinions recommendation of PET imaging of tau deposition in the aging human brain. , 2017 .
[2] L. Wilkins. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2017, Neurology.
[3] C. Jack,et al. Effect of intellectual enrichment on AD biomarker trajectories , 2016, Neurology.
[4] Daniel R. Schonhaut,et al. PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.
[5] A. Fagan,et al. Suspected non-Alzheimer disease pathophysiology — concept and controversy , 2016, Nature Reviews Neurology.
[6] C. Jack,et al. Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study , 2016, The Lancet Neurology.
[7] Jorge Sepulcre,et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.
[8] C. Escobar Cervantes,et al. [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.
[9] Jackson T. Wright,et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.
[10] M. Weiner,et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. , 2015, Brain : a journal of neurology.
[11] Keith A. Johnson,et al. Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.
[12] Kerstin Heurling,et al. [18F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid-β pathology , 2015, Alzheimer's & Dementia.
[13] G. Chételat,et al. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease , 2015, The Journal of Neuroscience.
[14] Karen M Rodrigue,et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. , 2015, JAMA.
[15] W. M. van der Flier,et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. , 2015, Brain : a journal of neurology.
[16] Clifford R. Jack,et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum , 2015, Brain : a journal of neurology.
[17] Christopher C Rowe,et al. Tau imaging: early progress and future directions , 2015, The Lancet Neurology.
[18] H. Braak,et al. PART is part of Alzheimer disease , 2015, Acta Neuropathologica.
[19] Simone Lista,et al. Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future , 2015, Expert review of neurotherapeutics.
[20] Robert A. Koeppe,et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.
[21] Janna H. Neltner,et al. Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.
[22] Miranka Wirth,et al. Vascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions , 2014, Neurology.
[23] Nick C Fox,et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.
[24] N. Laskaris,et al. Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease , 2014, Alzheimer's & Dementia.
[25] K. Blennow,et al. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry. , 2014, JAMA neurology.
[26] Young T. Hong,et al. Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. , 2014, JAMA neurology.
[27] C. Jack,et al. Biomarker Modeling of Alzheimer’s Disease , 2013, Neuron.
[28] Cindee M. Madison,et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. , 2013, JAMA neurology.
[29] Nick C Fox,et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration , 2013, The Lancet Neurology.
[30] Gaël Chételat,et al. Alzheimer disease: Aβ-independent processes—rethinking preclinical AD , 2013, Nature Reviews Neurology.
[31] K. Blennow,et al. Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections , 2013, Journal of Neurology.
[32] K. Blennow,et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. , 2012, Archives of neurology.
[33] C. Jack,et al. An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.
[34] J. Gunter,et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2012, Neurology.
[35] L. Whalley,et al. Childhood socioeconomic status and adult brain size: Childhood socioeconomic status influences adult hippocampal size , 2012, Annals of neurology.
[36] C. Jack,et al. Modifiable factors that alter the size of the hippocampus with ageing , 2012, Nature Reviews Neurology.
[37] Nazahah Mustafa,et al. The balance between cognitive reserve and brain imaging biomarkers of cerebrovascular and Alzheimer's diseases. , 2011, Brain : a journal of neurology.
[38] Dietmar R. Thal,et al. Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.
[39] Nick C Fox,et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[40] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[41] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[42] M. Albert,et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[43] Nick C. Fox,et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup , 2011 .
[44] J. Morris,et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .
[45] C. Duyckaerts. Tau pathology in children and young adults: can you still be unconditionally baptist? , 2011, Acta Neuropathologica.
[46] Nick C Fox,et al. Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.
[47] J. Trojanowski,et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.
[48] Wendy R. Sanhai,et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.
[49] J. Duffy,et al. Fluorodeoxyglucose F18 positron emission tomography in progressive apraxia of speech and primary progressive aphasia variants. , 2010, Archives of neurology.
[50] M. Weiner,et al. Relationships between biomarkers in aging and dementia , 2009, Neurology.
[51] S. Leurgans,et al. The neuropathology of probable Alzheimer disease and mild cognitive impairment , 2009, Annals of neurology.
[52] W. M. van der Flier,et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.
[53] Magda Tsolaki,et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study , 2009, The Lancet Neurology.
[54] H. Soininen,et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.
[55] Scott A. Small,et al. Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis , 2008, Neuron.
[56] W. Jagust,et al. Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia , 2008, Annals of neurology.
[57] C. Jack,et al. MRI correlates of neurofibrillary tangle pathology at autopsy , 2008, Neurology.
[58] S. DeKosky,et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.
[59] P. Scheltens,et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.
[60] A. Fagan,et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.
[61] K. Blennow,et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury , 2006, Neurology.
[62] H. Soininen,et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. , 2006, Brain : a journal of neurology.
[63] K. Blennow,et al. Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt–Jakob disease , 2006, Neurobiology of Aging.
[64] Anders Wallin,et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. , 2005, Clinical chemistry.
[65] R. Gräsbeck. The evolution of the reference value concept , 2004, Clinical chemistry and laboratory medicine.
[66] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[67] J. Whitworth,et al. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension , 2003, Journal of hypertension.
[68] K. Blennow,et al. CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.
[69] K. Blennow,et al. CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.
[70] K. Blennow,et al. Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy , 2003 .
[71] K. Blennow,et al. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. , 2003, Movement disorders : official journal of the Movement Disorder Society.
[72] K. Blennow,et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke , 2001, Neuroscience Letters.
[73] K. Blennow,et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.